Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mylan Inc Issues FY 2013 Guidance In Line With Analysts' Estimates


Wednesday, 27 Feb 2013 04:53pm EST 

Mylan Inc announced that for fiscal 2013, it expects total revenue to be in the range of $7.000 - $7.400 billion, EBITDA to be in the range of $1.900 - $2.100 billion, net income to be in the range of $1.060 - $1.180 billion and diluted EPS to be in the range of $2.75-$2.95. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $7.162 billion, EBITDA of $2.083 billion, net income of $1.147 billion and EPS of $2.80 for fiscal 2013. 

Latest Key Developments in Pharmaceuticals

Company Quote

50.2
-0.505 -1.00%
11 Jul 2014